TELO2 and central nervous system cancer: Validation of TELO2 using qRT-PCR, Western blot and immunohistochemical (IHC) staining supports the overexpression of TELO2 mRNA and protein level in high-grade gliomas, implying that TELO2 correlates with adverse outcome in high-grade gliomas.